These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 24433137)

  • 1. Ticagrelor as an alternative in clopidogrel-associated neutropenia.
    Shah R; Keough LA; Belalcazar-Portacio A; Ramanathan KB
    Platelets; 2015; 26(1):80-2. PubMed ID: 24433137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist.
    Azmoon S; Angiolillo DJ
    Catheter Cardiovasc Interv; 2013 Feb; 81(2):232-42. PubMed ID: 22581463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prasugrel as an alternative for clopidogrel-associated neutropenia.
    Khangura S; Gordon WL
    Can J Cardiol; 2011; 27(6):869.e9-11. PubMed ID: 21791365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New antiplatelet agents in the treatment of acute coronary syndromes.
    Sabouret P; Taiel-Sartral M
    Arch Cardiovasc Dis; 2014 Mar; 107(3):178-87. PubMed ID: 24630752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ticagrelor: a safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis?
    Samoš M; Fedor M; Kovář F; Duraj L; Stančiaková L; Galajda P; Staško J; Kubisz P; Mokáň M
    Blood Coagul Fibrinolysis; 2016 Mar; 27(2):117-20. PubMed ID: 26340464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
    Capranzano P; Mehran R; Tamburino C; Stone GW; Dangas G
    Hosp Pract (1995); 2010 Nov; 38(4):38-43. PubMed ID: 21068525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Evidence on Platelet P2Y12 Receptor Inhibitors: Is There Still a Role for Clopidogrel in 2015?
    Qutub MA; Chong AY; So DY
    Can J Cardiol; 2015 Dec; 31(12):1481-4. PubMed ID: 26243350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
    Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
    Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
    Steg PG; Harrington RA; Emanuelsson H; Katus HA; Mahaffey KW; Meier B; Storey RF; Wojdyla DM; Lewis BS; Maurer G; Wallentin L; James SK;
    Circulation; 2013 Sep; 128(10):1055-65. PubMed ID: 23900047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-stent thrombosis when switching ticagrelor to clopidogrel after percutaneous coronary intervention.
    Brice AE; Hernandez GA; Sanchez M; Haynick M; Mendoza CE
    Platelets; 2017 May; 28(3):305-309. PubMed ID: 27778525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of ticagrelor versus clopidogrel in acute coronary syndrome in Taiwan: A multicenter retrospective pilot study.
    Chen IC; Lee CH; Fang CC; Chao TH; Cheng CL; Chen Y; Yu CL; Lin CC; Lin CY; Li YH;
    J Chin Med Assoc; 2016 Oct; 79(10):521-30. PubMed ID: 27339180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ticagrelor. Acute coronary syndromes: nothing new.
    Prescrire Int; 2011 Oct; 20(120):229-33. PubMed ID: 21970081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome.
    Torngren K; Ohman J; Salmi H; Larsson J; Erlinge D
    Cardiology; 2013; 124(4):252-8. PubMed ID: 23594617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of prasugrel in a patient with clopidogrel hypersensitivity.
    Peppard SR; Held-Godgluck BM; Beddingfield R
    Ann Pharmacother; 2011 Oct; 45(10):e54. PubMed ID: 21896923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Steg PG; James S; Harrington RA; Ardissino D; Becker RC; Cannon CP; Emanuelsson H; Finkelstein A; Husted S; Katus H; Kilhamn J; Olofsson S; Storey RF; Weaver WD; Wallentin L;
    Circulation; 2010 Nov; 122(21):2131-41. PubMed ID: 21060072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
    Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
    J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ticagrelor: a novel reversible oral antiplatelet agent.
    Nawarskas JJ; Clark SM
    Cardiol Rev; 2011; 19(2):95-100. PubMed ID: 21285670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.
    Anderson SD; Shah NK; Yim J; Epstein BJ
    Ann Pharmacother; 2010 Mar; 44(3):524-37. PubMed ID: 20124464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
    Kohli P; Wallentin L; Reyes E; Horrow J; Husted S; Angiolillo DJ; Ardissino D; Maurer G; Morais J; Nicolau JC; Oto A; Storey RF; James SK; Cannon CP
    Circulation; 2013 Feb; 127(6):673-80. PubMed ID: 23277305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.